It spread explosively to cover more than 1,000 acres of river and tributaries and jump, carried by the boats and trailers of ...

Intellia Therapeutics reported further progress with two treatments that are now ensconced in Phase III of testing. Click ...

CuriosityStream has transformed into a profitable, high-growth company with a scalable business. Read more on the company's ...

Received overwhelming shareholder approval with 99.9% of votes cast in favorSimplified structure benefits shareholders through strengthened shareholder alignment, enhanced governance, significant cash ...

Cargo handling at Iran’s southeastern Sistan and Baluchestan Province ports rose by 2.1 percent in the past Iranian year. A ...

BAKU, Azerbaijan, May 12. Turkish Foreign Minister Hakan Fidan held a telephone conversation with Russian Foreign Minister ...

NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025 MET-233i, a monthly, ultra-long ac ...